Revolution Medicines, Inc. $RVMD Shares Acquired by New York State Common Retirement Fund

New York State Common Retirement Fund lifted its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 39.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 119,807 shares of the company’s stock after acquiring an additional 33,821 shares during the period. New York State Common Retirement Fund owned 0.06% of Revolution Medicines worth $5,595,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in Revolution Medicines by 45.1% in the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock valued at $39,000 after purchasing an additional 260 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Revolution Medicines by 0.3% during the 2nd quarter. California State Teachers Retirement System now owns 140,077 shares of the company’s stock worth $5,153,000 after buying an additional 437 shares during the last quarter. CWM LLC raised its position in shares of Revolution Medicines by 171.3% during the 2nd quarter. CWM LLC now owns 917 shares of the company’s stock valued at $34,000 after buying an additional 579 shares during the period. Avanza Fonder AB lifted its holdings in Revolution Medicines by 17.5% in the third quarter. Avanza Fonder AB now owns 4,335 shares of the company’s stock valued at $202,000 after acquiring an additional 647 shares during the last quarter. Finally, Voya Investment Management LLC lifted its holdings in Revolution Medicines by 2.0% in the third quarter. Voya Investment Management LLC now owns 47,534 shares of the company’s stock valued at $2,220,000 after acquiring an additional 921 shares during the last quarter. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have issued reports on RVMD. Raymond James Financial raised their target price on Revolution Medicines from $72.00 to $76.00 and gave the stock a “strong-buy” rating in a research note on Friday, October 17th. UBS Group upgraded shares of Revolution Medicines to a “strong-buy” rating in a report on Thursday, December 4th. Royal Bank Of Canada initiated coverage on shares of Revolution Medicines in a research note on Monday, November 3rd. They set an “outperform” rating and a $77.00 target price for the company. Wedbush reissued an “outperform” rating on shares of Revolution Medicines in a research note on Friday, January 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a report on Thursday, January 22nd. Four analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Revolution Medicines presently has a consensus rating of “Buy” and an average price target of $78.94.

Insider Buying and Selling

In related news, COO Margaret A. Horn sold 75,000 shares of Revolution Medicines stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $100.56, for a total value of $7,542,000.00. Following the completion of the transaction, the chief operating officer directly owned 141,053 shares in the company, valued at approximately $14,184,289.68. This trade represents a 34.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Jack Anders sold 10,000 shares of the company’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $98.00, for a total value of $980,000.00. Following the sale, the chief financial officer owned 108,065 shares in the company, valued at approximately $10,590,370. This trade represents a 8.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 213,792 shares of company stock valued at $17,948,440 in the last three months. 8.20% of the stock is currently owned by insiders.

Revolution Medicines Trading Down 0.4%

Shares of RVMD stock opened at $96.15 on Friday. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $124.49. The company has a 50 day moving average price of $92.12 and a 200 day moving average price of $63.35. The stock has a market capitalization of $18.59 billion, a P/E ratio of -18.60 and a beta of 1.01. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.05 and a current ratio of 8.05.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.22). During the same period in the prior year, the business posted ($0.94) EPS. Equities research analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.